Key facts
- This page summarizes Myoungil Cha's Form 4 filing for TANDEM DIABETES CARE INC (TNDM).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 Jun 2024, 16:42.
Myoungil Cha - 17 Jun 2024 Form 4 Insider Report for TANDEM DIABETES CARE INC (TNDM)
- Reporting relationship
- Director
- Issuer ticker
- TNDM
- Reported as of
- 17 Jun 2024
- Net transaction value
- +$79,282
- SEC form
- 4
- Accepted by SEC
- 20 Jun 2024, 16:42:17 UTC
- Prior SEC filing
- 24 May 2024
- Next SEC filing
- 23 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Rachel Malina, Attorney-in-Fact for Myoungil Cha
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Myoungil Cha filed Form 4 for TANDEM DIABETES CARE INC (TNDM) on 20 Jun 2024.
Change
- Previous filing in this sequence was filed on 24 May 2024.
- Current net transaction value: +$79,282.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TNDM
transaction
Common Stock
Options Exercise
- Transaction value
- $79,282
- Shares
- +1,749
- Change %
- +30%
- Price
- $45.33
- Shares after
- 7,563
- Date
- 17 Jun 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TNDM
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -1,749
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 1,749
- Date
- 17 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,749
- Exercise price
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Awarded on June 15, 2022 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan).
Footnote F2
Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.
Footnote F3
The total number of shares subject to the RSU will vest over a period of three years in equal annual installments on the anniversary of the grant, subject to the terms of the 2013 Plan.